Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - Novo Nordisk

Next Previous
X
Search
Drug Profile

Liraglutide - Novo Nordisk

Alternative Names: LATIN T1D; Liraglutide; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease; Smoking withdrawal
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 31 Dec 2022 Novo Nordisk has patent protection for liraglutide in USA and European Union till 2023
  • 03 Aug 2022 Novo Nordisk in collaboration with Cedars-Sinai Medical Center completes a phase II trial in Parkinson disease (Treatment-experienced) (SC) in USA (NCT02953665) (U1111-1173-0106)
  • 25 May 2022 Novo Nordisk completes a phase II trial in Smoking withdrawal in USA (Injection) (NCT03712098)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top